## 075025116

1

## **HOUSE BILL NO. 2178**

House Amendments in [] - January 22, 2007

A BILL to amend and reenact § 54.1-3450 of the Code of Virginia, relating to Schedule III controlled substances.

Patron Prior to Engrossment—Delegate Morgan

Referred to Committee on Health, Welfare and Institutions

10

11

12 13

14

15 16

17

18 19

20

21

22

23

24

25

26 27

28

29

30

31

32 33

34

35

36

**37** 

38

39

40

41

42

43 44

45

46 47

48

49

50

51

52

53

54

55

56 57

23

4

5

Be it enacted by the General Assembly of Virginia:

1. That § 54.1-3450 of the Code of Virginia is amended and reenacted as follows:

§ 54.1-3450. Schedule III.

The controlled substances listed in this section are included in Schedule III:

1. Unless specifically exempted or listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules;

Any compound, mixture or preparation containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and one or more other active medicinal ingredients which are not listed in Schedules II through V;

Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital or any salt of amobarbital, secobarbital, or pentobarbital and approved by the Food and Drug Administration for marketing only as a suppository;

Chlorhexadol;

Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355);

Embutramide;

Ketamine, its salts, isomers, and salts of isomers (some other names: [+-] -2-[2-chlorophenyl]-2-[methylamino]-cyclohexanone);

Lysergic acid;

Lysergic acid amide;

Methyprylon;

Sulfondiethylmethane;

Sulfonethylmethane:

Sulfonmethane; and

Tiletamine - zolazepam combination product or any salt thereof.

- 2. Nalorphine.
- 3. Unless specifically excepted or unless listed in another schedule:
- a. Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts thereof:

Buprenorphine.

b. Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

/21/10 7:22

HB2178E 2 of 3

**59** Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more 60 than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;

Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic

Not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Benzphetamine;

Chlorphentermine;

Methandrostenolone

(17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);

17alpha-methyl-3beta,17beta-dihydroxy-5a-androstane;

17alpha-methyl-3alpha,17beta-dihydroxy-5a-androstane;

17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene);

Methenolone (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);

Clortermine:

61

62

63 64

65

66

67

68

69

70 71

**72** 

73 74

**76** 

**78** 

80

81

82

114

115

116

117

118

119

120

Phendimetrazine.

- 5. The Board may except by regulation any compound, mixture, or preparation containing any stimulation or depressant substance listed in subsection A from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.
- 6. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical

```
83
 84
      designation:
 85
         Anabolic steroids, including, but not limited to:
 86
         3beta,17-dihydroxy-5a-androstane;
         3alpha,17beta-dihydroxy-5a-androstane;
 87
 88
         5alpha-androstan-3,17-dione;
 89
         1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-ene);
 90
         1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-1-ene);
 91
         4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);
 92
         5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);
 93
         1-androstenedione ([5alpha]-androst-1-en-3,17-dione);
         4-androstenedione (androst-4-en-3,17-dione);
 94
 95
         5-androstenedione (androst-5-en-3,17-dione);
 96
         Bolasterone (7alpha,17alpha-dimenthyl-17beta-hydroxyandrost-4-en-3-one);
 97
         Boldenone (Dehydrotestosterone) (17beta-hydroxyandrost-1,4,-diene-3-one);
 98
         Calusterone (7beta, 17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
 99
         Clostebol (4-Chlorotestosterone) (Chlorotestosterone) (4-chloro-17beta-hydroxyandrost-4-en-3-one);
100
         Dehydrochloromethyltestosterone (4-chloro-17beta-hydroxy-17alpha-methyl-androst-1,4-dien-3-one);
101
         Delta1-dihydrotestosterone (1-testosterone) (17beta-hydroxy-5alpha-androst-1-en-3-one);
102
         Dromostanolone (Drostanolone) (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
         Ethylestrenol (17alpha-ethyl-17beta-hydroxyestr-4-ene);
103
104
         Fluoxymesterone (9-fluoro-17alpha-methyl-11beta,17beta-dihydroxyandrost-4-en-3-one);
105
         Formyldienolone
                                                                                          (Formebolone)
106
      (2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-dien-3-one);
107
         Furazabol (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);
108
         13-beta-ethyl-17alpha-hydroxygon-4-en-3-one;
         4-hydroxytestosterone (4,17beta-dihydroxy-androst-4-en-3-one);
109
         4-hydroxy-19-nortestosterone (4,17beta-dihydroxy-estr-4-en-3-one);
110
         Mestanolone (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);
111
         Mesterolone (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);
112
         Methandriol (methylandrostenediol) (17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene);
113
```

(Methandienone)

17alpha-methyl-4-hydroxynandrolone (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);

(Dehydromethyltestosterone)

```
121
         Methyldienolone (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);
122
         Methyltrienolone (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);
123
         17-Methyltestosterone (Methyltestosterone) (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);
124
         Mibolerone (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
125
         17 alpha-methyl-deltal-dihydrotestosterone
126
     (17bbeta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) (17-alpha-methyl-1-testosterone);
127
         Nandrolone (19-Nortestosterone) (17beta-hydroxyestr-4-en-3-one);
128
         19-nor-4-androstenediol (3beta,17beta-dihydroxyestr-4-ene);
129
         19-nor-4-androstenediol (3alpha,17beta-dihydroxyestr-4-ene);
130
         19-nor-5-androstenediol (3beta,17beta-dihydroxyestr-5-ene);
131
         19-nor-5-androstenediol (3alpha,17beta-dihydroxyestr-5-ene);
132
         19-nor-4-androstenedione (estr-4-en-3,17-dione);
         19-nor-5-androstenedione (estr-5-en-3,17-dione);
133
134
         Norbolethone (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);
135
         Norclostebol (4-chloro-17beta-hydroxyestr-4-en-3-one);
136
         Norethandrolone (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);
137
         Normethandrolone (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);
138
         Oxandrolone (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);
139
         Oxymesterone (Oxymestrone) (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);
140
         Oxymetholone
                                                                                         (Anasterone)
141
     (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-androstan-3-one);
142
         Stanolone (4-Dihydrotestosterone) (Dihydrotestosterone) (17beta-hydroxy-androstan-3-one);
143
         Stanozolol (Androstanazole) (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-pyrazole);
144
         Stenbolone (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);
145
         Testolactone (1-Dehydrotestololactone) (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
146
     lactone);
147
         Testosterone (17beta-hydroxandrost-4-en-3-one);
         Tetrahydrogestrinone (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);
148
149
         Trenbolone (Trienbolone) (Trienbolone) (17beta-hydroxyestr-4,9,11-trien-3-one); and
150
         Any salt, ester, or ether of a drug or substance described or listed in this paragraph. However, such
151
     term does not include an anabolic steroid which is expressly intended for administration through
152
     implants to cattle or other nonhuman species and which has been approved by the United States
153
     Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or
154
     distributes any such steroid for human use, such person shall be considered to have prescribed,
155
     dispensed, or distributed an anabolic steroid within the meaning of this subsection.
```

7. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration.

156

157

158

159

160

161

[2. That the provisions of this act may result in a net increase in periods of imprisonment or commitment. Pursuant to § 30-19.1:4, the estimated amount of the necessary appropriation cannot be determined for periods of imprisonment in state adult correctional facilities and is \$0 for periods of commitment to the custody of the Department of Juvenile Justice.]